The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.Acta dermato-venereologica · 2021
   Trial
2. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021
   Trial
3. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.Acta dermato-venereologica · 2021
   Trial
4. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020
   Trial
5. Aquaporin 3 inhibition attenuates imiquimod-induced psoriatic symptoms in a murine model.Molecular biology reports · 2025
   Article
6. Memory Cells in Infection and Autoimmunity: Mechanisms, Functions, and Therapeutic Implications.Vaccines · 2025
   Review
7. A Mini-Review on the Symptoms and Pathogenesis of Psoriasis and Recent Nanotechnological Developments in its Treatment Strategies.Current pharmaceutical design · 2025
   Review
8. Patient-reported Outcomes and Burden of Disease in Paediatric Patients with Psoriasis: Real-world Data from EU5 and US.Acta dermato-venereologica · 2023
   Article
9. Identification immune response genes in psoriasis after treatment with secukinumab.BMC medical genomics · 2023
   Article
10. The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation.PharmacoEconomics - open · 2022
    Article
11. Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.Dermatology and therapy · 2022
    Article
12. Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial.Nutrients · 2021
    Article
13. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan.The Journal of dermatology · 2021
    Observational
14. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).Dermatology and therapy · 2018
    Article
15. Human CD8 T-cell activation in acute and chronic chikungunya infection.Immunology · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.